Brain

The purpose of this study is to investigate the impact of genetic and non-genetic risk factors for Alzheimer’s disease (AD), evaluate differential effects of sex on AD risk, and predict diagnosis of AD using dementia risk scores derived from genetic and non-genetic risk factors.

The study will involve a demographic questionnaire, cognitive (memory and thinking) testing and collection of saliva and/or blood sample for genetic analysis.

In people with amyotrophic lateral sclerosis (ALS), faster disease progression and decreased lifespan have been linked to immune system dysregulation and inflammatory processes. COYA302 is a subcutaneous injection drug therapy which has been shown to improve immune system regulation and suppress inflammation in people with ALS. This study will assess the safety, effects and long-term efficacy of COYA302 administered to patients with ALS.

MicroRNAs (miRNAs), small noncoding regulators controlling approximately 60 per cent of human genes, have strong early diagnostic potential due to their ability to modulate complex gene networks and stability in extracellular fluids. However, blood-based miRNA findings remain inconsistent, highlighting the need for alternative, scalable biofluids. This study aims to demonstrate the translational potential of tear-fluid miRNAs as non-invasive, clinically relevant early biomarkers for diagnosing sporadic Alzheimer’s disease.

The purpose of this study is to improve how we use magnetic resonance imaging (MRI) to assess new treatments for multiple sclerosis (MS) in the future, and to advance personalized care. Advanced MRI research involves gathering different sequences or images not typically collected on a routine clinical MRI. These images will allow the research team to specifically look at myelin in fine detail along with other measures of brain structure and overall brain health.

The purpose of this study is to independently measure the annualized relapse rate (ARR) with administration of frexalimab compared to a daily oral dose of teriflunomide in male and female participants with relapsing forms of multiple sclerosis who are 18 to 55 years of age at the time of enrollment. 

The purpose of this study is to collect biospecimens (fecal, urine, blood) and clinical data to serve as a resource for future research on Parkinson’s disease and other movement disorders. The careful collection, storage and retrieval of biospecimens and medical information for research projects are critical for improving understanding of healthy development and disease mechanisms and the subsequent development of effective treatments. Biospecimens from this biobank will be made available for ethically-approved studies.

The purpose of this study is to develop a means, via a wearable sensor, to detect the subtle physiological changes that may occur before wearing off (WO) of a Parkinson's disease treatment called levodopa become consciously felt to allow for medication to be taken and absorbed in time to prevent the WO from occurring.

The purpose of this study is to assess the efficacy of two drug treatments measured by annualized adjudicated relapse rate (ARR) in participants with relapsing forms of MS.

The purpose of this study is to investigate the impact of genetic and non-genetic risk factors for Alzheimer’s disease (AD), evaluate differential
effects of sex on AD risk, and predict diagnosis of AD using dementia risk scores derived from genetic and nongenetic risk factors.

The purpose of this study is to evaluate the efficacy and safety of ocrelizumab ( Ocrevus®) compared with placebo in participants with primary progressive multiple sclerosis (PPMS).